Prices are updated after-hours

Health Technology 2020 - 11 - 06

ABIOMED, Inc.

ABMD | $381.02 0.06% 0.07%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (758.37% volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec Filling | Patents | 1536 employees

(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

heart brands

add to watch list Paper trade email alert is off

Aerie Pharmaceuticals, Inc.

AERI | $15.25 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees

(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

eye treatment

Drugs

Rhopressa (netarsudil)
Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

add to watch list Paper trade email alert is off

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-82.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Horizon Therapeutics Public Limited Company

HZNP | $116.3 0.03% 29M

Health Technology

(0.0% 1d) (0.0% 1m) (5.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (383.01% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 26,632,068,258
http://www.horizontherapeutics.com
Sec Filling | Patents | 1200 employees

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

add to watch list Paper trade email alert is off

Humanigen, Inc.

HGEN | $0.0361 -61.5% 120M

Health Technology

(0.0% 1d) (0.0% 1m) (-78.1% 1y) (0.0% 2d) (0.0% 3d) (-81.1% 7d) (23283.32% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 4,298,793
http://www.humanigen.com
Sec Filling | Patents | 2 employees

(US) Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

cancer gene therapies t-cell treatment ceiling

add to watch list Paper trade email alert is off

ImmunoGen, Inc.

IMGN | News | $31.23 0.03% 49M

Health Technology

(0.0% 1d) (0.0% 1m) (658.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
Sec Filling | Patents | 75 employees

(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

cancer antibody

add to watch list Paper trade email alert is off

InVivo Therapeutics Holdings Corp.

NVIV | $0.3207 -25.16% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-56.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-98.2% volume)
Earnings Calendar:
Market Cap: $ 995,917
http://www.invivotherapeutics.com
Sec Filling | Patents | 6 employees

(US) Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.

spinal cord msa treatment

add to watch list Paper trade email alert is off

Jounce Therapeutics, Inc.

JNCE | $1.88 -2.59% -1.85% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-1.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 98,954,680
http://www.jouncetx.com
Sec Filling | Patents | 130 employees

(US) Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

cancer immunotherapy t-cell ceiling

add to watch list Paper trade email alert is off

Endo International plc

ENDP | News | $0.2926 -9.6%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

cardiovascular women health nervous system women brands msa injection

add to watch list Paper trade email alert is off

Entasis Therapeutics Holdings Inc.

ETTX | $2.19 -0.46% 0.46%

Health Technology

(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
Sec Filling | Patents | 47 employees

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

batteries battery msa antibacterial injection

add to watch list Paper trade email alert is off

Epizyme, Inc.

EPZM | $1.47 -1.34% 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 247,496,185
http://www.epizyme.com
Sec Filling | Patents | 203 employees

(US) Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

cancer ovarian cancer t-cell lungs genetic leukemia ceiling

Drugs

TAZVERIK (tazemetostat)

add to watch list Paper trade email alert is off

Quotient Limited

QTNT | $0.38 2.73% -5.45%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (6319.76% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 51,604,836
http://www.quotientbd.com
Sec Filling | Patents | 418 employees

(CH) Quotient Ltd. is a commercial-stage diagnostics company. It provides immunohematology products to hospitals and blood banks. The firm develops, manufactures and sells conventional reagent products to equipment manufacturers. It engages in transfusion diagnostics, which focuses on blood grouping and serological disease screening. The company was founded on January 18, 2012 and is headquartered in Eysins, Switzerland.

diagnostics

add to watch list Paper trade email alert is off

Spectrum Pharmaceuticals, Inc.

SPPI | $1.03 -0.97% 0

Health Technology

(0.0% 1d) (0.0% 1m) (12.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (83.0% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 211,403,099
http://www.sppirx.com
Sec Filling | Patents | 146 employees

(US) Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.

acquisitions brands

Drugs

EVOMELA (Melphalan)
KHAPZORY (levoleucovorin)

add to watch list Paper trade email alert is off

Surgalign Holdings, Inc.

SRGA | $0.1829 -50.36% 8.7M

Health Technology

(0.0% 1d) (0.0% 1m) (-74.3% 1y) (0.0% 2d) (-9.1% 3d) (0.0% 7d) (-54.59% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,690,130
http://www.surgalign.com
Sec Filling | Patents | 935 employees

Surgalign Holdings, Inc. is a global medical technology company, which engages in designing, developing and manufacturing biologic metal and synthetic implants worldwide. It focuses on delivering spine solutions that drive clinical and economic outcomes. The company markets its products throughout the United States and other countries worldwide through an expanding network of independent distributors. The company was founded in February 1998 and is headquartered in Deerfield, IL.

add to watch list Paper trade email alert is off

ViewRay, Inc.

VRAY | $0.025 -39.9% -61.87% 110M

Health Technology

(0.0% 1d) (0.0% 1m) (-97.8% 1y) (0.0% 2d) (0.0% 3d) (-39.9% 7d) (32.05% volume)
Earnings Calendar: 2023-08-01
Market Cap: $ 4,585,051
http://www.viewray.com
Sec Filling | Patents | 309 employees

(US) ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

magnetic resonance radiation therapy treatment

add to watch list Paper trade email alert is off

Mirati Therapeutics, Inc.

MRTX | $58.7 -0.17% 0.34% 0

Health Technology

(0.0% 1d) (0.0% 1m) (36.0% 1y) (0.0% 2d) (-0.1% 3d) (0.0% 7d) (-41.54% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 4,117,670,342
http://www.mirati.com
Sec Filling | Patents | 111 employees

(US) Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

cancer immunology genetic

add to watch list Paper trade email alert is off

Orchard Therapeutics plc

ORTX | $16.7 0.0% 370K

Health Technology

(0.0% 1d) (0.0% 1m) (247.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 38,010,937
http://orchard-tx.com
Sec Filling | Patents | 252 employees

(United Kingdom) Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

gene therapies urea treatment

add to watch list Paper trade email alert is off

MedAvail Holdings Inc.

MDVL 4 | $1.8 -0.56% 250K

Health Technology

(0.0% 1d) (0.0% 1m) (597.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (187.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,905,040
https://medavail.com
Sec Filling | Patents | 15 employees

(US) MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

optical

add to watch list Paper trade email alert is off

Abeona Therapeutics Inc.

ABEO | News | $3.395 -53.87% -116.79% 5.5M

Health Technology

(0.0% 1d) (-53.9% 1m) (4.6% 1y) (0.0% 2d) (-53.7% 3d) (-54.7% 7d) (436.24% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 92,870,351
http://www.abeonatherapeutics.com
Sec Filling | Patents | 88 employees

(US) Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

skin gene therapies

add to watch list Paper trade email alert is off

Seagen Inc.

SGEN | $228.74 0.1% 20M

Health Technology

(0.0% 1d) (0.0% 1m) (12.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 42,934,025,652
http://www.seattlegenetics.com
Sec Filling | Patents | 1605 employees

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

cancer antibody treatment